Publications by the researcher in collaboration with José Luis Martín Ventura (14)

2022

  1. Implication of miR-155-5p and miR-143-3p in the Vascular Insulin Resistance and Instability of Human and Experimental Atherosclerotic Plaque

    International journal of molecular sciences, Vol. 23, Núm. 18

2018

  1. Potential role of insulin receptor isoforms and IGF receptors in plaque instability of human and experimental atherosclerosis

    Cardiovascular Diabetology, Vol. 17, Núm. 1

2016

  1. Expression of insulin receptor (IR) A and B isoforms, IGF-IR, and IR/IGF-IR hybrid receptors in vascular smooth muscle cells and their role in cell migration in atherosclerosis

    Cardiovascular Diabetology, Vol. 15, Núm. 1

2009

  1. Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis

    Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225

2008

  1. Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

    American Journal of Cardiology, Vol. 102, Núm. 1, pp. 12-18

2006

  1. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

    Journal of Cardiovascular Pharmacology, Vol. 47, Núm. 1, pp. 60-69

  2. El tratamiento con dosis altas de atorvastatina disminuye la inflamación en la aterosclerosis carotídea humana

    Clínica e investigación en arteriosclerosis, Vol. 18, Núm. 1, pp. 18-23

  3. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB

    Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149

2005

  1. HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

    Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475

  2. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2004

  1. Estatinas, inflamación y lesión aterosclerótica

    Nefrologia, Vol. 24, Núm. SUPPL.4, pp. 17-20

  2. NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients with Carotid Atherosclerosis: Potential Implication in Plaque Instability

    Stroke, Vol. 35, Núm. 2, pp. 458-463

  3. Propiedades anti-inflamatorias e inmunomoduladoras de las estatinas

    Nefrologia, Vol. 24, Núm. SUPPL.1, pp. 48-49

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58